Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Tromsø, Norway, 04 April 2019 - Biotec Pharmacon's (OSE: Biotec) subsidiary, Biotec BetaGlucans, has renewed its M-Glucan® contract with its largest customer within its Animal Health business.
The Company will continue to supply and assist its long-standing customer, a major player in the Animal Health sector. Expected revenues, depending on the sales of the customer to its end-users, are approximately NOK 20m annually.
Using beta-glucans to safely and effectively enhance the immune system of farmed animals has been a core activity for Biotec Pharmacon for 30 years. The M-Glucan® product has a variety of applications to improve animals' resistance to disease and to strengthen their growth rate. Biotec Pharmacon's beta-glucan product is well-documented in the animal feed industry. It is supported by over 60 publications and numerous animal trials - including fish and a variety of mammals - verifying its safety and mechanism of action.
Christian Jørgensen, CEO, said:
"We are proud to continue our long-term business relationship with this highly respected supplier of animal feed. It confirms not only the quality of our products, but also that our organization can operate and compete at the highest level in this sector."
"This renewed contract has secured a steady revenue stream for Biotec going forward."
- ENDS -
For more information, please contact:
Biotec Pharmacon
Christian Jørgensen, CEO Tel: +47 47 79 24 57
Email: christian.jorgensen@biotec.no
Instinctif Partners
Melanie Toyne-Sewell / Dr Tel: +44 207 457 2020
Christelle Kerouedan / Deborah Email: Biotecpharmacon@instinctif.com
Bell
About Biotec Pharmacon ASA
Biotec Pharmacon is a Norwegian life sciences company focused on specialized, novel enzyme and immunomodulating beta-glucan technology.
The Biotec Pharmacon Group is creating value from innovation in life science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its technologies capitalize on more than three decades of world-class research at the Arctic University of Tromsø to offer niche and high tech products in several biotech segments.
ArcticZymes develops, manufactures and commercialises novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.
Biotec BetaGlucans develops, produces and markets immunomodulating beta-glucans addressing high unmet healthcare needs, such as chronic wound healing and as an adjuvant in vaccines against certain types of cancer relapse.
Listed on the Oslo Stock Exchange since 2005 under the [Biotec] ticker, Biotec Pharmacon is headquartered in Tromsø, Norway, in the SIVA Innovation Centre.
Biotec Pharmacon's unique IP and capabilities are protected via a large portfolio of patents around both enzyme and beta-glucan products.
For more information, please visit the website: www.biotec.no.
About Biotec BetaGlucans
BetaGlucans develops, produces and markets immunomodulating beta-1,3/1,6-glucan (BG) products derived from the cell wall of the Saccharomyces cerevisiae.
The active pharmaceutical ingredients display immunomodulatory properties addressing high unmet healthcare needs, such as chronic wound healing or cancer.
Soluble BetaGlucan (SBG®) has been developed as the active ingredient in the wound healing product (Woulgan®) and is also being tested in a R&D programme as an adjuvant for immunotherapeutic cancer treatments.
For more information, please visit: https://biotec.no/about-us/biotec-betaglucans/.